Cancer Therapeutics Market is estimated to reach at $180,193 million by 2026
The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.
• Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.
• An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
• By Application
o Blood Cancer
o Lung Cancer
o Colorectal Cancer
o Prostate Cancer
o Breast Cancer
o Cervical Cancer
o Head and Neck Cancer
o Glioblastoma
o Malignant Meningioma
o Mesothelioma
o Melanoma
o Others
• By Top Selling Drugs
o Revlimid
o Avastin
o Herceptin
o Rituxan
o Opdivo
o Gleevec
o Velcade
o Imbruvica
o Ibrance
o Zytiga
o Alimta
o Xtandi
o Tarceva
o Perjeta
o Temodar
o Others
• By Region
o North America
§ U.S.
§ Canada
o Europe
§ Germany
§ France
§ UK
§ Italy
§ Spain
§ Rest of Europe
o Asia-Pacific
§ Japan
§ China
§ India
§ Australia
§ South Korea
§ Taiwan
§ Rest of Asia-Pacific
o LAMEA
§ Latin America
§ Middle-East
§ Africa
The list of key players operating in this market include:
• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• AbbVie, Inc.
• Johnson & Johnson
• Celgene Corporation
• Astellas Pharma, Inc.
• Pfizer, Inc.
• Novartis AG
• Merck KGaA
• Eli Lilly and Company
The other players included in the value chain analysis (and not included in the report) include:
• AstraZeneca plc
• Bayer AG
• Takeda Pharmaceutical Company Limited
Visit For More Information : Click Here
